The purpose of this study is to investigate potential metabolic effects of resveratrol in obese healthy men with non-alcoholic fatty liver disease. The investigators hypothesize that resveratrol will: * decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion * decrease liver fat content * increase insulin sensitivity The investigators will look at changes in: * lipid turnover (VLDL-TG kinetics, palmitate kinetics, indirect calorimetry) * liver fat content (MR liver spectroscopy) * insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp) * body composition (DXA and MRI) * lipase activity and fat cell size (fat biopsy from abdominal and femoral adipose tissue)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
26
500 mg 3 times daily for six month
1 placebo tablet 3 times daily for six month
Department of Endocrinology and Internal Medicine
Aarhus C, Denmark
Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance
\- Changes from baseline after treatment with either resveratrol or placebo
Time frame: six month
Basal and insulin stimulated free fatty acid (FFA) and glucose turnover
\- Changes from baseline after treatment with either resveratrol or placebo
Time frame: six month
VLDL-TG oxidation
\- Changes from baseline after treatment with either resveratrol or placebo
Time frame: six month
Body composition (fat mass, fat-free mass, percent fat, visceral fat mass)
\- Changes from baseline after treatment with either resveratrol or placebo
Time frame: six month
lipoprotein lipase activity and fat cell size in abdominal and femoral adipose tissue biopsy
\- Changes from baseline after treatment with either resveratrol or placebo
Time frame: six months
Baseline data
\- Comparison of baseline data between intervention group and control group
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.